SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Invesco QQQ Trust Series 1 - Units of beneficial interest

The Invesco QQQ Trust is experiencing heightened volatility and community skepticism as market participants debate the credibility of shifting geopolitical deadlines regarding the conflict in Iran and the Strait of Hormuz. Investors are actively questioning whether recent price action is a product of fundamental market strength or artificial manipulation driven by speculative trading and inconsistent executive messaging.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Trump Media & Technology Group is trending as investors and community members react to President Trump's aggressive social media rhetoric regarding the escalating conflict with Iran, including threats to target civilian infrastructure. Discussions are dominated by intense political polarization, with many users debating the effectiveness of his foreign policy, the accuracy of reported military mission outcomes, and the broader economic implications for oil markets and inflation.

SPDR S&P 500 ETF TRUST - Units of undivided interest in SPDR Trust Series 1

The market is reacting to headlines about potential ceasefire negotiations, leading to significant volatility as participants debate whether these reports are genuine developments or part of a broader cycle of headline-driven manipulation. The community remains deeply divided, with many traders expressing skepticism about the credibility of the reports and questioning if the ongoing geopolitical tensions are being used to influence short-term price action.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is currently trending due to intensifying speculation regarding a potential buyout or major partnership, fueled by activist pressure from Shah Capital to unlock shareholder value. While the company's core technology remains a focal point of community discussion, investor frustration is high due to ongoing volatility and silence from leadership regarding the status of key assets like the CIC vaccine.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bear 3X ETF

Direxion Daily Semiconductor Bear 3X Shares

Direxion Daily Semiconductor Bear 3X Shares (SOXS) is seeing intense trading activity as investors weigh the semiconductor sector's high valuation against geopolitical tensions and concerns over a potential AI bubble. Community discussion is split between those aggressively scalping the volatility for quick gains and bears positioning for a major market correction, with many traders closely monitoring semiconductor earnings and macroeconomic data as potential catalysts for a breakdown.

Wave Life Sciences Ltd. is a clinical-stage biotechnology company, which focuses on developing its proprietary RNA medicines platform and PRISM. It also develop and commercialize a pipeline RNA medicines in a variety of therapeutic areas. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.

Wave Life Sciences Ltd.

Wave Life Sciences Ltd

Wave Life Sciences is currently trending due to its innovative WVE-007 obesity program, which aims to provide a differentiated 'muscle-sparing' alternative to traditional GLP-1 therapies through RNA interference. Investors and the biotech community are actively discussing the company's potential as a prime acquisition target as major pharmaceutical firms scramble to secure next-generation obesity assets before looming patent cliffs.

iShares Trust - iShares Semiconductor ETF

iShares Semiconductor ETF

iShares Semiconductor ETF (SOXX) is currently a focal point for intense debate, as investors weigh sustained demand for AI-driven infrastructure against technical indicators suggesting the sector may be overextended. The community remains deeply divided, with bulls pointing to robust long-term growth and consistent dip-buying as signs of a 'buy the dip' market, while skeptics warn of a speculative bubble, citing concerns over high valuations, trade policy impacts, and potential mean reversion.

Direxion Shares ETF Trust - Direxion Small Cap Bear 3X ETF

Direxion Daily Small Cap Bear 3X Shares

The community is actively trading TZA to hedge against small-cap volatility and shifting economic expectations, with many users debating the sustainability of recent rallies and potential market downturns. Discussions heavily emphasize using inverse ETFs like TZA as a strategic tool to capitalize on market dips, while others express caution regarding the long-term decay risks inherent in holding leveraged products.

Strategy, Inc. engages in the provision of enterprise analytics and mobility software. The firm designs, develops, markets, and sells software platforms through licensing arrangements and cloud-based subscriptions and related services. Its product packages include Hyper. The company was founded by Michael J. Saylor and Sanjeev K. Bansal on November 17, 1989, and is headquartered in Tysons Corner, VA.

Strategy Inc. - VR PRF PERPETUAL USD 100 - Ser A

Strategy Inc Variable Rate Series A Perpetual Stretch Preferred

Strategy Inc. (STRC) is trending as investors capitalize on its perpetual preferred series, which offers a double-digit yield and serves as a liquidity engine for aggressive Bitcoin accumulation. While the community is actively debating the sustainability of this 'digital credit' flywheel and its potential impact on Bitcoin price action, many are treating the instrument as a high-yield vehicle to park capital while the company scales its treasury holdings.

United States Oil Fund LP - United States Oil Fund

United States Oil Fund

The United States Oil Fund is trending amid intense market volatility driven by escalating geopolitical tensions in the Middle East, specifically the blockage of the Strait of Hormuz and reports of strikes on critical energy infrastructure. Investors are closely monitoring a looming policy deadline and conflicting headlines regarding potential ceasefires, fueling a debate among the community between positioning for a structural oil supply crisis or betting on a rapid de-escalation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Summit Therapeutics drew heavy retail interest on Tuesday after its partner, Akeso, reported that ivonescimab (AK112), a closely watched lung cancer drug, helped patients live longer in a key late-stage trial.Akeso said the final analysis of the Phase III study in patients with EGFR-mutated, advanced non-squamous non-small cell lung cancer who had already failed EGFR-TKI therapy showed ivonescimab extended overall survival, meeting the trial’s main goal with a clear and meaningful benefit.&nbsp;Detailed data will be presented at an upcoming medical conference.The update came alongside Akeso’s first-half earnings and drove its Hong Kong-listed shares up as much as 5.92% on Wednesday. Meanwhile, Summit, which holds U.S. rights to ivonescimab, rose as much as 14% Tuesday on the news.&nbsp;While the drug is already approved in China, Summit is running a similar trial with a broader, global population to pave the way for an approval in the U.S.Ivonescimab has already won two approved indications in China: for EGFR-mutated NSCLC after EGFR-TKI therapy, and as monotherapy for PD-L1-positive advanced NSCLC.&nbsp;The drug has been included in clinical treatment guidelines, and Akeso has launched over 30 trials, including 13 Phase III studies and six head-to-head comparisons with PD-(L)1 therapies.Bernstein analysts led by Rebecca Liang called the survival data “a positive surprise,” noting that whether the drug could extend overall survival “has been the center of debate for AK112 since last year,” Bloomberg&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-08-27/akeso-s-lung-cancer-drug-hits-key-goal-in-china-study">reported</a>.&nbsp;They added it could be the biggest positive catalyst for Akeso since the company announced ivonescimab had outperformed Merck &amp; Co.’s top-selling cancer drug in a separate trial.On Stocktwits, retail sentiment was ‘extremely bullish’ for Summit Therapeutics amid ‘extremely high’ message volume, while Akeso drew ‘bullish’ sentiment with ‘high’ activity.One user speculated that Summit shares could reach $35 by&nbsp;the end of the week.&nbsp;<stembedurl>https://stocktwits.com/___dog___/message/626653621</stembedurl>Another suggested the stock was still digesting the overall survival news and argued it should already be trading above $30.<stembedurl>https://stocktwits.com/BooEmmy/message/626614344</stembedurl>While&nbsp;<a href="https://stocktwits.com/symbol/SMMT">Summit’s stock</a> has risen 51.2% so far in 2025,&nbsp;<a href="https://stocktwits.com/symbol/AKESF">Akeso’s U.S.-listed shares</a> have more than tripled over the same period.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

This Image Is A Part Of A Series On Pulmonary Pathologies. (Photo By BSIP/UIG Via Getty Images)

Summit Draws Frenzied Retail Chatter After Akeso Drug Shows Survival Benefit In Lung Cancer; Retail Sees More Upside

Analysts at Bernstein called the survival data “a positive surprise,” framing it as Akeso’s biggest catalyst since the drug previously outperformed Merck’s top-selling cancer therapy.

Equity

Akeso, Inc. Is an investment company, which engages in the research and development, production, and sale of biopharmaceuticals products. It operates through the following geographical segments: Chinese Mainland, USA, and Other Regions. The company was founded by Yu Xia, Peng Zhang, Baiyong Li, and Zhongmin Wang in March 2012 and is headquartered in Zhongshan, China.

Akeso Inc

Opendoor ($OPEN)

Strategy ($MSTR)

American Eagle ($AEO)

Ondas Inc. ($ONDS)

The stock that proved the power of the crowd. Fueled by community energy and social momentum, this winner captivated retail investors regardless of what the "experts" or traditional fundamentals had to say.

AKESF
Akeso Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest AKESF News

AKESFAkeso Inc